Insider Selling: Kewaunee Scientific (NASDAQ:KEQU) CEO Sells 1,000 Shares of Stock

Kewaunee Scientific Corporation (NASDAQ:KEQU) CEO Thomas David Hull III sold 1,000 shares of the company’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $43.62, for a total value of $43,620.00. Following the completion of the sale, the chief executive officer owned 41,573 shares of the company’s stock, valued at $1,813,414.26. This trade represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Thomas David Hull III also recently made the following trade(s):

• On Tuesday, September 23rd, Thomas David Hull III sold 721 shares of Kewaunee Scientific stock. The stock was sold at an average price of $44.00, for a total value of $31,724.00.
• On Friday, September 19th, Thomas David Hull III sold 773 shares of Kewaunee Scientific stock. The stock was sold at an average price of $45.34, for a total value of $35,047.82.
• On Thursday, September 18th, Thomas David Hull III sold 652 shares of Kewaunee Scientific stock. The stock was sold at an average price of $46.00, for a total value of $29,992.00.

Kewaunee Scientific Trading Down 0.8%

NASDAQ:KEQU opened at $43.48 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.32 and a quick ratio of 1.63. The firm has a market capitalization of $124.79 million, a price-to-earnings ratio of 10.53 and a beta of 0.75. Kewaunee Scientific Corporation has a one year low of $30.33 and a one year high of $71.33. The business has a fifty day moving average price of $53.39 and a 200-day moving average price of $45.47.

Kewaunee Scientific (NASDAQ:KEQU) last posted its quarterly earnings data on Wednesday, September 10th. The technology company reported $1.10 EPS for the quarter. The firm had revenue of $71.10 million during the quarter. Kewaunee Scientific had a return on equity of 25.65% and a net margin of 4.68%.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Kewaunee Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in shares of Kewaunee Scientific by 2,605.9% in the 4th quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock valued at $28,000 after acquiring an additional 443 shares during the last quarter. IFP Advisors Inc lifted its stake in Kewaunee Scientific by 61.5% in the first quarter. IFP Advisors Inc now owns 945 shares of the technology company’s stock worth $37,000 after purchasing an additional 360 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Kewaunee Scientific in the second quarter worth about $60,000. Wedbush Securities Inc. bought a new stake in Kewaunee Scientific in the second quarter worth about $232,000. Finally, Morgan Dempsey Capital Management LLC lifted its stake in Kewaunee Scientific by 41.8% in the second quarter. Morgan Dempsey Capital Management LLC now owns 4,229 shares of the technology company’s stock worth $247,000 after purchasing an additional 1,247 shares during the last quarter. Institutional investors own 32.69% of the company’s stock.

Kewaunee Scientific Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.